Table 1.
Demographic and Clinical Characteristics of Participants at the Time of Transient Elastography Measurement, Stratified by BMI Category
| Lean (BMI <25 kg/m2) | Overweight/Obese (BMI ≥25 kg/m2) | |
|---|---|---|
| Characteristics | N = 204 | N = 212 |
| Median age, years (IQR) | 51 (42–59) | 52 (46–59) |
| Female sex (%) | 52 (25.5) | 61 (28.8) |
| Region of origin (%) | ||
| Europe | 154 (75.5) | 151 (71.2) |
| Africa | 27 (13.2) | 52 (24.5) |
| Asia | 17 (8.3) | 5 (2.4) |
| Other | 6 (2.9) | 4(1.9) |
| HIV Transmission Group (%) | ||
| MSM | 112 (54.9) | 90 (42.5) |
| Heterosexual | 81 (39.7) | 106 (50.0) |
| PWID | 2 (1.0) | 2 (0.9) |
| Other/unknown | 9 (4.4) | 14 (6.6) |
| Arterial hypertension (%) | 49 (24.0) | 72 (34.0) |
| Diabetes (%) | 9 (4.4) | 28 (13.2) |
| Dyslipidemia (%) | 59 (28.9) | 98 (46.2) |
| History of cardiovascular disease (%) | 12 (5.9) | 16 (7.6) |
| Median BMI, kg/m2 (IQR) | 22.1 (20.8–23.9) | 29.6 (26.6–31.5) |
| Median ALT, U/L (IQR) | 28.0 (19.0–30.5) | 33.2 (22.0–40.0) |
| Median triglycerides, mmol/L (IQR) | 1.63 (0.9–1.9) | 2.30 (1.1–2.6) |
| Hazardous alcohol consumption (%) | 41 (22.2) | 42 (22.0) |
| Median current CD4+ count, cells/µL (IQR) | 740 (535–897) | 792 (577–985) |
| Median CD4 nadir in cells/µL (IQR) | 252 (100–347) | 245 (128–342) |
| HIV viral load <50 copies/mL (%) | 189 (92.6) | 198 (93.4) |
| Median eGFR in mL/min (IQR) | 91 (75–104) | 89 (71–100) |
| ART duration, years (IQR) | 13.3 (7.0–20.0) | 12.0 (6.0–19.0) |
| Current ART regimen (%) | ||
| 3TC/ABC/DTG | 52 (25.5) | 44 (20.8) |
| FTC/TAF/BIC | 27 (13.2) | 30 (14.2) |
| FTC/TAF/DTG | 22 (10.8) | 38 (17.9) |
| Other | 99 (48.5) | 97 (45.8) |
| No treatment | 4 (2.0) | 3 (1.4) |
| Exposed to TAF (%) | 104 (51.0) | 128 (60.4) |
| Exposed to InSTI (%) | 146 (71.6) | 146 (68.9) |
| Ever exposed to PI (%) | 112 (54.9) | 115 (54.3) |
| Ever exposed to AZT/DDI/D4T (%) | 95 (46.6) | 88 (41.5) |
Abbreviations: ABC, abacavir; ALT, alanine aminotransferase; ART, antiretroviral therapy; AST, aspartate aminotransferase; AZT/DDI/D4T, zidovudine/didanosine/stavudine; BIC, bictegravir; BMI, body mass index; CV, cardiovascular; DTG, dolutegravir; eGFR, estimated glomerular filtration rate; FTC, emtricitabine; HIV, human immunodeficiency virus; InSTI, integrase-strand transfer inhibitor; IQR, interquartile range; MSM, men who have sex with men; PI, protease inhibitor; PWID, patients who inject drugs; TAF, tenofovir alafenamide; 3TC, lamivudine.